A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS).

Trial Profile

A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS).

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Dec 2013

At a glance

  • Drugs Asimadoline (Primary)
  • Indications Irritable bowel syndrome
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 15 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 09 Nov 2012 Planned end date changed from 1 Dec 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
    • 07 Feb 2012 Planned end date changed from 1 Sep 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top